Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Pancreatic Ductal × Drug Therapy × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 69 Stomach Neoplasms 48 Pancreatic Neoplasms 44 Rectal Neoplasms 40 Esophageal Squamous Cell Carcinoma 36 Esophageal Neoplasms 31 Neoplasm Metastasis 22 Colonic Neoplasms 20 Neoplasms 12 Cholangiocarcinoma 11 Gastrointestinal Neoplasms 10 Adenocarcinoma Of Esophagus 9 Liver Neoplasms 8 Breast Neoplasms 7 Carcinoma, Hepatocellular 6 Biliary Tract Neoplasms 5 Anus Neoplasms 5 Lung Neoplasms 4 Head and Neck Neoplasms 4 Gastrointestinal Diseases 4 Digestive System Neoplasms 4 Carcinoma, Squamous Cell 4 Carcinoma, Non-Small-Cell Lung 4 Ovarian Neoplasms 3 Melanoma 3 Lymphoma 3 Intestinal Neoplasms 3 Drug-Related Side Effects and Adverse Reactions 3 Adenocarcinoma 3 Sarcoma 2

Interventions

Gemcitabine 15 130-nm albumin-bound paclitaxel 10 Albumin-Bound Paclitaxel 7 Oxaliplatin 5 Paclitaxel 4 Leucovorin 4 Fluorouracil 4 Carboplatin 4 Cisplatin 3 Cetuximab 3 Bevacizumab 3 pembrolizumab 2 napabucasin 2 Pemetrexed 2 PEGPH20 2 MK-4721 2 Irinotecan 2 tremelimumab 1 selinexor 1 relacorilant 1 ponatinib 1 neratinib 1 irinotecan sucrosofate 1 folfirinox 1 ensituximab 1 durvalumab 1 contrast agent BR1 1 cobimetinib 1 ceritinib 1 cc-486 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04146441 2023-01-19

PDAC

St. Olavs Hospital

Phase 2 Completed

Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡